Patient Adherence

Malaria News Today 2020-10-21: perspectives on falciparum, transfusion issues, drug effectiveness | 10/22/2020

… but can be dangerous in mild cases. And with severe malaria delay in treatment is a major risk. Malaria parasites can be surprisingly diverse, even in one home. Health system performance, drug quality and patient adherence are key factors in the effectiveness of anti-malarials. Read more on each article or abstract in the links provided. The impact of delayed treatment of uncomplicated P. falciparum malaria on progression to severe …

Project SIM: Smart Mobile Health | 9/25/2020

The specialized platform supports patient adherence and engagement in treatment through remote monitoring and better access to educational resources. The clinical study protocol was approved by the Rio de Janeiro State University and the City of Rio de Janeiro’s Health Secretariat. Challenge The existing public health care infrastructure in Brazil was primarily created to deal with acute diseases. Today, a di erent health care system is needed to cope with …

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability | 9/25/2020

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability September 25, 2020 …

Text messages with educational videos significantly improve patient adherence to newly prescribed medications | 9/25/2020

A new study by VUCA Health, the Pharmacy Quality Alliance (PQA), and Liberty Software found that educational videos sent through text messages enhanced patient adherence to newly prescribed medications. A new study by VUCA Health, the Pharmacy Quality Alliance (PQA), and Liberty Software found that educational videos sent through text messages enhanced patient adherence to newly prescribed medications. In the study, which involved more than 6,300 newly initiated prescriptions for …

EASD: Weekly Insulin Icodec for T2D Shows Efficacy in Phase II Trial | Physicians Weekly | 9/24/2020

… currently the most commonly used basal insulin analogue.” As the authors pointed out, once-weekly insulin icodec would help patients better manage their insulin and reduce their injections from 365/year to 52. Better patient adherence to treatment regimens has been shown in studies of injectable once-weekly glucagon-like receptor peptide 1 (GLP-1) receptor agonists over once-daily treatment, Rosenstock and colleagues noted, and patient satisfaction was also …

illuminate.health Selected as the Technology Platform of Choice to Power the Mednovate Connect Telepharmacy Solution | PR Newswire | 9/23/2020

… ask drug-related questions and monitor their overall care progress. To support patient-driven medication management, Mednovate Connect realized early on that they needed a user-friendly telehealth solution to document medication therapy, improve patient adherence through a personal notification system, allow for pharmacist consults via text, video or phone and to be compatible with a patient’s electronic health record (EHR). Illuminate.health’s dynamic digital health assistant, Med Guide, proved to …

illuminate.health Selected as the Technology Platform of Choice to Power the Mednovate Connect Telepharmacy Solution | 9/23/2020

… ask drug-related questions and monitor their overall care progress. To support patient-driven medication management, Mednovate Connect realized early on that they needed a user-friendly telehealth solution to document medication therapy, improve patient adherence through a personal notification system, allow for pharmacist consults via text, video or phone and to be compatible with a patient’s electronic health record (EHR). Illuminate.health’s dynamic digital health assistant, Med Guide, proved to …

illuminate.health Selected as the Technology Platform of Choice to Power the Mednovate Connect Telepharmacy Solution | 9/23/2020

… ask drug-related questions and monitor their overall care progress. To support patient-driven medication management, Mednovate Connect realized early on that they needed a user-friendly telehealth solution to document medication therapy, improve patient adherence through a personal notification system, allow for pharmacist consults via text, video or phone and to be compatible with a patient’s electronic health record (EHR). Illuminate.health’s dynamic digital health assistant, Med Guide, proved to …

Text Messages With Educational Videos Significantly Improve Patient Adherence to Newly Prescribed Medications | 9/22/2020

Text Messages With Educational Videos Significantly Improve Patient Adherence to Newly Prescribed Medications [September 22, 2020] Text Messages With Educational Videos Significantly Improve Patient Adherence to Newly Prescribed Medications LAKE MARY, Fla. , Sept. 22, 2020 /PRNewswire/ – Educational videos delivered via text message significantly improve patient adherence to newly prescribed medications, according to a new study by VUCA Health, the Pharmacy Quality Alliance (PQA), and Liberty Software. Results of the study …

“HIV may not be eradicated, but a cure will come to control it better” | 9/22/2020

… HIV cocktail was terrible! Currently they are being given a combination of three pills in one as a first-line medication and we are waiting for a new drug to arrive that would improve patient adherence (that is to say, it would allow virus carriers to have better control of the correct dose of the medications and the effect would be more effective), a fundamental aspect to keeping the viral …

Study evaluates effect of videos with educational information about the patient’s prescription | 9/22/2020

Educational videos delivered via text message significantly improve patient adherence to newly prescribed medications, according to a new study by VUCA Health, the Pharmacy Quality Alliance (PQA), and Liberty Software. Results of the study will be presented at the American Public Health Association’s Virtual Annual Meeting and Expo on October 27. Primary medication nonadherence (PMN) occurs when a new medication is prescribed, but the patient does not obtain the medication …

Datacubed Health Raises Capital to Create the Future of Patient Engagement | Business Wire | 9/14/2020

… of neuroeconomics, which takes an interdisciplinary approach to understanding how humans make decisions. Together with their team, Kleger and Dr. Glimcher are focused on reducing the risk that poor data collection or lack of patient adherence to the trial’s protocols prevents or delays a drug coming to market. “We’re excited to partner with Datacubed and work with its leadership team and employees to be the preeminent provider of patient engagement …

Multiple Myeloma Market Size Forecast, Epidemiology Analysis, Emerging Drug Uptake and Key Companies Assessment by DelveInsight | PR Newswire | 9/11/2020

… Multiple Myeloma Epidemiology and Market indicates that the impressive growth in market size is due to the rise in incident cases of Multiple Myeloma in 8MM, incorporation of immune-therapies in treatment landscape increased patient adherence and adoption of newer therapies. Also, rich emerging pipeline, better diagnosis, rising awareness and expected increase in investment in the R&D activities are some additional factors that are going to fuel the market …

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability | 9/11/2020

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability September 11, 2020 …

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability | 9/10/2020

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability September 10, 2020 …

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability | 9/10/2020

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability September 10, 2020 …

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability | 9/9/2020

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability September 08, 2020 …

What Types of Physical Function Predict Program Adherence in Older Adults? | 9/9/2020

Patient adherence to an exercise program is a long-standing issue. What do you know about adherence? How can we, as nurses, influence adherence in older adults? Are there indicators that might predict adherence? Liu and Miyawaki describe the nationwide EnhanceFitness program (36,000+ participants) and identify the association of participants’ function in three baseline physical function tests and adherence to the program. Read What Types of Physical Function Predict Program …

LEP Patient Adherence Increases When Interpreters Are Used to Communicate with Healthcare Providers | 9/8/2020

Careers LEP Patient Adherence Increases When Interpreters Are Used to Communicate with Healthcare Providers The Joint Commission explains, “effective communication allows patients to participate more fully in their care. When a patient understands what is being said about his or her care, treatment, and services, that patient is more likely to fulfill critical health care responsibilities.” A study published in JAMA Internal Medicine analyzing language concordance and patient adherence found …

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability | 9/7/2020

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability September 07, 2020 …

New England Journal of Medicine Publishes Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis | PR Newswire | 9/7/2020

… Company’s estimates of the size of the potential markets for ARIKAYCE or brensocatib or in data the Company has used to identify physicians; expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE; failure to obtain regulatory …

New England Journal of Medicine Publishes Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis | Business & Finance | heraldchronicle.com | PR Newswire | 9/7/2020

… Company’s estimates of the size of the potential markets for ARIKAYCE or brensocatib or in data the Company has used to identify physicians; expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE; failure to obtain regulatory …

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability | 9/6/2020

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability September 06, 2020 …

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability | 9/5/2020

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability September 05, 2020 …

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability | 9/5/2020

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability September 05, 2020 …

Remote Monitoring

Project SIM: Smart Mobile Health | 9/25/2020

The specialized platform supports patient adherence and engagement in treatment through remote monitoring and better access to educational resources. The clinical study protocol was approved by the Rio de Janeiro State University and the City of Rio de Janeiro’s Health Secretariat. Challenge The existing public health care infrastructure in Brazil was primarily created to deal with acute diseases. Today, a di erent health care system is needed to cope with …

Medication Adherence

illuminate.health Selected as the Technology Platform of Choice to Power the Mednovate Connect Telepharmacy Solution | PR Newswire | 9/23/2020

… medication management, Mednovate Connect realized early on that they needed a user-friendly telehealth solution to document medication therapy, improve patient adherence through a personal notification system, allow for pharmacist consults via text, video or … provide virtual access during the COVID-19 pandemic to improve medication adherence, avoid adverse drug effects and reduce overall health costs for patient care.” “illuminate.health is humbled to be chosen as the platform of choice …

Digital Health

illuminate.health Selected as the Technology Platform of Choice to Power the Mednovate Connect Telepharmacy Solution | PR Newswire | 9/23/2020

CARMEL, Ind. illuminate.health , a digital health assistant platform designed to help people live healthier, today announced that the company’s Med Guide medication therapy optimization offering will power Mednovate Connect , a real-time telepharmacy solution for … a user-friendly telehealth solution to document medication therapy, improve patient adherence through a personal notification system, allow for pharmacist consults via text, video or phone and to be compatible with a patient’s electronic health …

Telehealth

illuminate.health Selected as the Technology Platform of Choice to Power the Mednovate Connect Telepharmacy Solution | PR Newswire | 9/23/2020

telehealth solution to document medication therapy, improve patient adherence through a personal notification system, allow for pharmacist consults via text, video or phone and to be compatible with a patient’s electronic health record (EHR). Illuminate.health’s dynamic digital health assistant, Med Guide, proved to be an attractive solution to power this initiative as the tool, along with Mednovate’s trained clinical pharmacists, can help patients avoid medication-related complications and increase use …

Medication Management

illuminate.health Selected as the Technology Platform of Choice to Power the Mednovate Connect Telepharmacy Solution | PR Newswire | 9/23/2020

… announced that the company’s Med Guide medication therapy optimization offering will power Mednovate Connect , a real-time telepharmacy solution for medication management. Through Med Guide’s artificial intelligence (AI) platform integration with Mednovate, high-risk patient … a user-friendly telehealth solution to document medication therapy, improve patient adherence through a personal notification system, allow for pharmacist consults via text, video or phone and to be compatible with a patient’s electronic health …

COVID-19

Datacubed Health Raises Capital to Create the Future of Patient Engagement | Business Wire | 9/14/2020

… life sciences sectors. With Sterling’s investment, Datacubed has now raised nearly $30 million from its founders, angel investors, and Sterling. COVID-19 Creates Critical Market Opportunity for eCOA Clinical trials are incredibly complex, often involving … reducing the risk that poor data collection or lack of patient adherence to the trial’s protocols prevents or delays a drug coming to market. “We’re excited to partner with Datacubed and work with its leadership …

NIH

Biotech CEOs pen standards for coronavirus trials, data disclosures amid FDA reputation crisis | FiercePharma | 9/3/2020

… are dependent upon the integrity, transparency and objective assessment of new data as they emerge,” they noted. Featured Webinar Increasing Patient Adherence for Isolated Populations During the Pandemic Formulation strategies focused on patient centric solutions … those statements. In treatment guidelines this week, a panel of NIH experts said there are “no data” to support the use of plasma as standard of care for COVID-19 patients. The FDA relied on …

Food and Drug Administration

Dozens of US hospitals poised to defy FDA’s directive on COVID plasma | FiercePharma | 9/3/2020

… Food and Drug Administration. Featured Webinar Increasing Patient Adherence for Isolated Populations During the Pandemic Formulation strategies focused on patient centric solutions featuring several panel speakers representing different perspectives including regulatory, excipients quality related to dose forms, and challenges regarding patience adherence and formulation strategies. Register Now The response comes amid concerns that the Trump administration pressured the FDA into approving broader use of convalescent plasma, which already has been …

Department of Health and Human Services

Rebuking FDA, NIH experts say ‘no data’ support plasma as a COVID-19 treatment | FiercePharma | 9/2/2020

… with high titers of SARS-CoV-2 antibodies compared with those who received plasma with low titers. Featured Webinar Increasing Patient Adherence for Isolated Populations During the Pandemic Formulation strategies focused on patient centric solutions … or “major advance,” statements made by President Donald Trump and Department of Health and Human Services Secretary Alex Azar, respectively, at a briefing where they announced the FDA’s emergency nod. FDA Commissioner Stephen Hahn. M.D …

Mental Health

Cordant Health Solutions Opens a New Addiction Treatment Pharmacy in Arizona | PR Newswire | 8/21/2020

… MAT as a key component of effective treatment for OUD. Despite the increasing need for services, the Substance Abuse and Mental Health Services Administration (SAMHSA) estimates that in 2017, only 19% of Americans who needed … efficient and effective in using drug testing programs to monitor patient adherence, reduce risk and improve patient outcomes. MEDIA CONTACT Tiffany Tuetken 303-570-4585 Related Images cordant-health-solutions.jpg Cordant Health Solutions Related Links Cordant Health …

Population Health

RenalytixAI to Collaborate with AstraZeneca to Improve Outcomes for Patients with Chronic Disease Nasdaq:RNLX | Globe Newswire | 8/21/2020

Population Health Management at the Icahn School of Medicine at Mount Sinai, and board member of RenalytixAI. “By using a more personalized approach, our initial goal is to help realize improved outcomes for more than 240,000 patients with chronic kidney disease within the Mount Sinai Health System.” RenalytixAI and AstraZeneca will use KidneyIntelX with the aim to: Help improve physician uptake and patient adherence to existing potassium-binding therapeutics and …

Mental Health Services

Cordant Health Solutions Opens a New Addiction Treatment Pharmacy in Arizona | PR Newswire | 8/21/2020

… MAT as a key component of effective treatment for OUD. Despite the increasing need for services, the Substance Abuse and Mental Health Services Administration (SAMHSA) estimates that in 2017, only 19% of Americans who needed … efficient and effective in using drug testing programs to monitor patient adherence, reduce risk and improve patient outcomes. MEDIA CONTACT Tiffany Tuetken 303-570-4585 Related Images cordant-health-solutions.jpg Cordant Health Solutions Related Links Cordant Health …

Health Management

RenalytixAI to Collaborate with AstraZeneca to Improve Outcomes for Patients with Chronic Disease Nasdaq:RNLX | Globe Newswire | 8/21/2020

Health Management at the Icahn School of Medicine at Mount Sinai, and board member of RenalytixAI. “By using a more personalized approach, our initial goal is to help realize improved outcomes for more than 240,000 patients with chronic kidney disease within the Mount Sinai Health System.” RenalytixAI and AstraZeneca will use KidneyIntelX with the aim to: Help improve physician uptake and patient adherence to existing potassium-binding therapeutics and other …

Readmissions

Care Dimensions Improves Quality of Life for Hospice Patients Using Telehealth | PR Newswire | 12/4/2019

patient adherence rates of nearly 90% and has been essential to their reduction of hospital readmissions and ED visits.” In the coming months, Care Dimensions’ clinical team will further expand their use of virtual visits, scheduling virtual visits following patient enrollment and installation to answer questions and ensure patient and caregiver comfort with the telehealth program. “The use of telehealth has enabled our team to personalize care to each patients …

Hospital Readmissions

Care Dimensions Improves Quality of Life for Hospice Patients Using Telehealth | PR Newswire | 12/4/2019

patient adherence rates of nearly 90% and has been essential to their reduction of hospital readmissions and ED visits.” In the coming months, Care Dimensions’ clinical team will further expand their use of virtual visits, scheduling virtual visits following patient enrollment and installation to answer questions and ensure patient and caregiver comfort with the telehealth program. “The use of telehealth has enabled our team to personalize care to each patients …

Electronic Health Records

Financial Contrast: OptimizeRx (NASDAQ:OPRX) and NetEase (NASDAQ:NTES) | 12/2/2019

patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient …

Molecular Diagnostics

Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon® Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer | BioSpace | 12/2/2019

… for CRC offers the highest sensitivity of all available screening strategies, the results of this micro-simulation model demonstrate that patient adherence and prescribed screening intervals heavily influence the long-term clinical effectiveness for all … laboratory. Epi proColon is recipient of the 2019 Excellence in Molecular Diagnostics by Corporate LiveWire’s Innovation and Excellence Awards. For more information on Epi proColon, visit www.epiprocolon.com . About Epigenomics Epigenomics is a molecular diagnostics company …

Medicare

Exact Sciences to participate in December investor conference | PR Newswire | 11/26/2019

… looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement, the anticipated results of our product development efforts … without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society …

Diagnostic Tests

Exact Sciences to participate in December investor conference | PR Newswire | 11/26/2019

… investor relations section of Exact Sciences’ website at www.exactsciences.com . About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing … future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement, the anticipated results of our product development efforts and the anticipated benefits of our acquisition of Genomic Health …

National Committee for Quality Assurance

Exact Sciences to participate in December investor conference | PR Newswire | 11/26/2019

… looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement, the anticipated results of our product development efforts … Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services and assess potential …

Patient Satisfaction

Mine Your EMR for Data and Improve Patient Safety | FierceHealthcare | 11/25/2019

… the risks of anticoagulation therapy. Anticoagulation therapy involves complex dosing, and it’s often further complicated by insufficient monitoring and inconsistent patient adherence. Tracking the patient education you give these patients will help you improve safety … or specialty to identify training opportunities. You can illustrate whether patient satisfaction scores went up when patient education was used more often. You can even compare how the timing of the education (where in the …

Patient Monitoring

The global autotransfusion devices market at a CAGR of almost 6% during the forecast period | PR Newswire | 11/25/2019

patient monitoring much simpler and cost-effective and contributes to higher patient adherence to health monitoring. Thus, all these factors have the potential to accelerate the growth of the global healthcare equipment market, including the global autotransfusion devices market. Moreover, several companies focus on the development of technological platforms that are integrated with autotransfusion systems to provide blood products to patients during surgical procedures This development is expected to have …

Patient Safety

Mine Your EMR for Data and Improve Patient Safety | FierceHealthcare | 11/25/2019

… business of helping patients, not running numbers, right?—but what if I told you this information could help you improve patient safety and outcomes? I recently teamed up with Vicki Maisonneuve, director of the Nursing … and it’s often further complicated by insufficient monitoring and inconsistent patient adherence. Tracking the patient education you give these patients will help you improve safety 1 . 2. Decide what (and who) to track. Now you …

Digital Therapeutics

Biofourmis Announces Acquisition of Biovotion AG, Completing Biovitals® Platform to Deliver Precise Interventions at the Right Time to Manage Patients with Complex Chronic Conditions | PR Newswire | 11/18/2019

… the Right Time to Manage Patients with Complex Chronic Conditions Acquisition of Biovotion establishes Biovitals® as the most comprehensive predictive digital therapeutics solution for healthcare providers, payers and pharmaceutical companies by combining best-in-class … 80% adherence rates among patients and study participants. The high patient adherence rate and accurate data collection of numerous clinical and non-clinical parameters are two of the primary reasons Biofourmis commonly uses the device …

Clinical Research

Biofourmis Announces Acquisition of Biovotion AG, Completing Biovitals® Platform to Deliver Precise Interventions at the Right Time to Manage Patients with Complex Chronic Conditions | PR Newswire | 11/18/2019

… disease; to demonstrate the value of and potentially complement pharmacotherapy; to provide cost-effective solutions for payers; and to advance clinical research. The lead product among Biovotion’s wearables is the clinical-grade Everion® device, which … 80% adherence rates among patients and study participants. The high patient adherence rate and accurate data collection of numerous clinical and non-clinical parameters are two of the primary reasons Biofourmis commonly uses the device …

Pfizer

Multiple Myeloma Market Size Forecast, Epidemiology Analysis, Emerging Drug Uptake and Key Companies Assessment by DelveInsight | PR Newswire | 9/11/2020

… due to the rise in incident cases of Multiple Myeloma in 8MM, incorporation of immune-therapies in treatment landscape increased patient adherence and adoption of newer therapies. Also, rich emerging pipeline, better diagnosis, rising awareness … Squibb, AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca etc. Patent expiry of multiple blockbuster drugs like Revlimid, Pomalyst, Darzalex and Kyprolis is on the lines to expire from 2026 …

Bristol-Myers Squibb

Multiple Myeloma Market Size Forecast, Epidemiology Analysis, Emerging Drug Uptake and Key Companies Assessment by DelveInsight | PR Newswire | 9/11/2020

… due to the rise in incident cases of Multiple Myeloma in 8MM, incorporation of immune-therapies in treatment landscape increased patient adherence and adoption of newer therapies. Also, rich emerging pipeline, better diagnosis, rising awareness … Companies fuelling the Multiple Myeloma market size growth are GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca etc. Patent expiry of multiple blockbuster drugs like Revlimid …

Merck

Multiple Myeloma Market Size Forecast, Epidemiology Analysis, Emerging Drug Uptake and Key Companies Assessment by DelveInsight | PR Newswire | 9/11/2020

… due to the rise in incident cases of Multiple Myeloma in 8MM, incorporation of immune-therapies in treatment landscape increased patient adherence and adoption of newer therapies. Also, rich emerging pipeline, better diagnosis, rising awareness … are GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca etc. Patent expiry of multiple blockbuster drugs like Revlimid, Pomalyst, Darzalex and Kyprolis is on the lines …

Amgen

Multiple Myeloma Market Size Forecast, Epidemiology Analysis, Emerging Drug Uptake and Key Companies Assessment by DelveInsight | PR Newswire | 9/11/2020

… due to the rise in incident cases of Multiple Myeloma in 8MM, incorporation of immune-therapies in treatment landscape increased patient adherence and adoption of newer therapies. Also, rich emerging pipeline, better diagnosis, rising awareness … Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca etc. Patent expiry of multiple blockbuster drugs like Revlimid, Pomalyst, Darzalex and Kyprolis is on the lines to expire from 2026 onwards, and …

GlaxoSmithKline

Multiple Myeloma Market Size Forecast, Epidemiology Analysis, Emerging Drug Uptake and Key Companies Assessment by DelveInsight | PR Newswire | 9/11/2020

… due to the rise in incident cases of Multiple Myeloma in 8MM, incorporation of immune-therapies in treatment landscape increased patient adherence and adoption of newer therapies. Also, rich emerging pipeline, better diagnosis, rising awareness … Key Companies fuelling the Multiple Myeloma market size growth are GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca etc. Patent expiry of multiple blockbuster drugs like …

AstraZeneca

Multiple Myeloma Market Size Forecast, Epidemiology Analysis, Emerging Drug Uptake and Key Companies Assessment by DelveInsight | PR Newswire | 9/11/2020

… due to the rise in incident cases of Multiple Myeloma in 8MM, incorporation of immune-therapies in treatment landscape increased patient adherence and adoption of newer therapies. Also, rich emerging pipeline, better diagnosis, rising awareness … Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca etc. Patent expiry of multiple blockbuster drugs like Revlimid, Pomalyst, Darzalex and Kyprolis is on the lines to expire from 2026 onwards, and this …

Bristol-Myers

Multiple Myeloma Market Size Forecast, Epidemiology Analysis, Emerging Drug Uptake and Key Companies Assessment by DelveInsight | PR Newswire | 9/11/2020

… due to the rise in incident cases of Multiple Myeloma in 8MM, incorporation of immune-therapies in treatment landscape increased patient adherence and adoption of newer therapies. Also, rich emerging pipeline, better diagnosis, rising awareness … Companies fuelling the Multiple Myeloma market size growth are GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca etc. Patent expiry of multiple blockbuster drugs like Revlimid …

AbbVie

Multiple Myeloma Market Size Forecast, Epidemiology Analysis, Emerging Drug Uptake and Key Companies Assessment by DelveInsight | PR Newswire | 9/11/2020

… due to the rise in incident cases of Multiple Myeloma in 8MM, incorporation of immune-therapies in treatment landscape increased patient adherence and adoption of newer therapies. Also, rich emerging pipeline, better diagnosis, rising awareness … Multiple Myeloma market size growth are GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca etc. Patent expiry of multiple blockbuster drugs like Revlimid, Pomalyst, Darzalex and …

Proteus Digital Health

From big deals to bankruptcy, a digital health unicorn falls short. Here’s what other startups can learn from Proteus | FierceHealthcare | 9/4/2020

… digital health venture capital firm Rock Health. But having a breakthrough technology is not enough to succeed. Case in point: Proteus Digital Health, a high-flying digital therapeutics startup that secured big pharmaceutical partnerships, raised … to monitor patients at home. The devices have a high patient adherence rate, according to the company. The company has secured deals with seven pharmaceutical companies and 10 health systems, to date. Health tech startups …

Exact Sciences

Exact Sciences to participate in September investor conference | PR Newswire | 9/1/2020

MADISON, Wis. Exact Sciences Corp. (Nasdaq: EXAS ) today announced that company management will participate in the following conference and invited investors to participate by webcast. Baird Global Healthcare Conference Fireside Chat on Wednesday, September 9 … future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement, and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances …

GSK

After another Kevzara fail in COVID-19, Sanofi and Regeneron shift their attention elsewhere | FiercePharma | 9/1/2020

… of its work advancing knowledge of the disease, R&D chief John Reed said in a statement. Featured Webinar Increasing Patient Adherence for Isolated Populations During the Pandemic Formulation strategies focused on patient centric solutions … Ronny Gal wrote on Monday. His team predicts the Sanofi/GSK partnership will earn around $2 billion in COVID-19 vaccine revenues during 2021 and 2022, with the number gradually declining in later years …

Boehringer Ingelheim

ESC: Merck’s Steglatro shows limited promise with heart failure hospitalization data | FiercePharma | 8/31/2020

… was originally intended to test Steglatro’s ability to match placebo in terms of diabetes patients’ cardiovascular safety. Featured Webinar Increasing Patient Adherence for Isolated Populations During the Pandemic Formulation strategies focused on patient centric solutions … group of added heart failure endpoints after Eli Lilly and Boehringer Ingelheim released data showing SGLT2 med Jardiance bettered heart failure patients’ CV outcomes. Unlike that study and others from Johnson & Johnson and AstraZeneca that …

Merck & Co

ESC: Merck’s Steglatro shows limited promise with heart failure hospitalization data | FiercePharma | 8/31/2020

Late to the party against its SGLT2 diabetes rivals, Merck & Co.’s Steglatro has also tracked way behind in the class’ growing presence in heart failure. Now, the drugmaker has posted new data showing Steglatro … in terms of diabetes patients’ cardiovascular safety. Featured Webinar Increasing Patient Adherence for Isolated Populations During the Pandemic Formulation strategies focused on patient centric solutions featuring several panel speakers representing different perspectives including regulatory, excipients …

Eli Lilly

ESC: Merck’s Steglatro shows limited promise with heart failure hospitalization data | FiercePharma | 8/31/2020

Patient Adherence for Isolated Populations During the Pandemic Formulation strategies focused on patient centric solutions featuring several panel speakers representing different perspectives including regulatory, excipients quality related to dose forms, and challenges regarding patience adherence and formulation strategies. Register Now The drugmaker later expanded the study—which was required by the FDA following Steglatro’s approval in late 2017—to include a group of added heart failure endpoints after Eli Lilly

Johnson & Johnson

ESC: Merck’s Steglatro shows limited promise with heart failure hospitalization data | FiercePharma | 8/31/2020

… was originally intended to test Steglatro’s ability to match placebo in terms of diabetes patients’ cardiovascular safety. Featured Webinar Increasing Patient Adherence for Isolated Populations During the Pandemic Formulation strategies focused on patient centric solutions … failure patients’ CV outcomes. Unlike that study and others from Johnson & Johnson and AstraZeneca that showed similar benefits, though, Steglatro’s study wasn’t set up to show superiority against placebo, a fact that limits the drug’s …

Quantzig

How Real World Evidence Analytics Can Accelerate COVID-19 Drug Discovery and Vaccine Trials | Quantzig | Business Wire | 7/23/2020

LONDON–(BUSINESS WIRE)–Jul 23, 2020– Quantzig, one of the world’s leading analytics solutions provider, committed to offering cutting-edge analytics solutions to help organizations institutionalize data-driven decision making. Quantzig’s real world evidence analytics solutions provide comprehensive insights on treatment pathways, patient adherence, disease progression, pricing levels and market access, drug safety, and patient engagement. All of which play a pivotal role in enhancing drug discovery and driving healthcare …

Propeller Health

Propeller gets green light to bundle its digital health tools with inhalers - MedCity News | 7/8/2020

Propeller Health received approval from the European Commission to co-package its digital health platform with Novartis’ Enerzair Breezhaler inhaler. Photo credit: Propeller Health European regulators gave Novartis and Propeller Health the green light to co-package their products, opening the door for digital health products and medications to be prescribed together for the first time. Propeller Health makes sensors that attach to inhalers. The software monitors patient adherence and …

Novartis

Propeller gets green light to bundle its digital health tools with inhalers - MedCity News | 7/8/2020

Propeller Health received approval from the European Commission to co-package its digital health platform with Novartis’ Enerzair Breezhaler inhaler. Photo credit: Propeller Health European regulators gave Novartis and Propeller Health the green light to co-package their products, opening the door for digital health products and medications to be prescribed together for the first time. Propeller Health makes sensors that attach to inhalers. The software monitors patient adherence and …

Oncotype

Exact Sciences schedules annual meeting, second quarter 2020 earnings call | PR Newswire | 7/8/2020

… relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of … future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement, and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances …

Genentech

Bristol Myers Squibb’s Zeposia and Janssen’s Ponesimod Could Be Early-Line Winners, While Biogen’s Vumerity Appears Relegated to Tolerability Switches Within the Fumarate Class | PR Newswire | 6/16/2020

… pandemic has had a high impact on their practice. Indeed, among the subset of neurologists who report decreased use of Genentech’s Ocrevus over the past three months, nearly all cite COVID-19 as a strong … of patient convenience may be overshadowed by potential shortcomings on patient adherence. Spherix will continue to track neurologists’ pre-market perceptions of ofatumumab as the anticipated FDA decision nears. About RealTime Dynamix™ RealTime Dynamix™: Multiple …

IQVIA

AllazoHealth names pharmaceutical industry analytics expert Mark Degatano to advisory board | PRWeb | 4/9/2020

… joining the company’s Advisory Board. “The AllazoHealth approach of using artificial intelligence effectively addresses an important, long-standing problem in patient adherence and engagement,” said Mr. Degatano. NEW YORK (PRWEB) April 09, 2020 AllazoHealth, a … at numerous data and service providers, including Symphony Health, Prognos, IQVIA, and Aptus Health. “The AllazoHealth approach of using artificial intelligence effectively addresses an important, long-standing problem in patient adherence and engagement,” said Mr …

AllazoHealth

AllazoHealth names pharmaceutical industry analytics expert Mark Degatano to advisory board | PRWeb | 4/9/2020

AllazoHealth names pharmaceutical industry analytics expert Mark Degatano to advisory board Share Article AllazoHealth, a company that uses artificial intelligence to help pharmaceuticals, payers, and pharmacies improve medication adherence and quality outcomes, announced today that pharmaceutical industry veteran Mark Degatano will be joining the company’s Advisory Board. “The AllazoHealth approach of using artificial intelligence effectively addresses an important, long-standing problem in patient adherence and engagement,” said Mr. Degatano. NEW …

OptimizeRx

Financial Contrast: OptimizeRx (NASDAQ:OPRX) and NetEase (NASDAQ:NTES) | 12/2/2019

20.90% Insider and Institutional Ownership 60.6% of OptimizeRx shares are held by institutional investors. Comparatively, 48.2% of NetEase shares are held by institutional investors. 8.4% of OptimizeRx shares are held by company insiders. Comparatively, 54.7 … communicate with healthcare providers. The company’s cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health …

Genomic Health

Exact Sciences to participate in December investor conference | PR Newswire | 11/26/2019

patient adherence efforts, expectations concerning payer reimbursement, the anticipated results of our product development efforts and the anticipated benefits of our acquisition of Genomic Health, including estimated synergies and other financial impacts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and …

Allscripts

OptimizeRx Reports Third Quarter 2019 Results | Globe Newswire | 11/5/2019

patient adherence to medications and better healthcare outcomes with real-time access to financial assistance, prior authorization, education and critical clinical information. OptimizeRx provides more than half of the ambulatory patient market with access to these benefits through leading EHR platforms like Allscripts, Amazing Charts and Quest, and directly via its mobile communications platform and digital therapeutics SaaS platform. For more information, follow the company on Twitter , LinkedIn or visit …

SVB Leerink

Coronavirus tracker: EU taps AstraZeneca for 400M vaccine doses; UK snares shots from J&J, Novavax | FiercePharma | 8/13/2020

… TV spot encouraging patients with heart attack symptoms to seek medical help despite their COVID-19 concerns. Featured Webinar Increasing Patient Adherence for Isolated Populations During the Pandemic Formulation strategies focused on patient centric solutions … billion annual vaccine sales highs that consensus estimates have predicted, SVB Leerink analyst Mani Faroohar figures. A strong phase 3 update and emergency nod for the shot in the fourth quarter are “broadly expected,” but …

Insmed Announces Closing of Public Offering of Common Stock | PR Newswire | 6/27/2019

… purposes, which may include the acquisition or in‑license of additional compounds, product candidates, technology or businesses. Morgan Stanley & Co. LLC, SVB Leerink LLC and Goldman Sachs & Co. LLC acted as joint book-running managers for … rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer …

Goldman Sachs

The Medicines Company (MDCO) CEO Mark Timney on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 10/30/2019

… Umer Raffat - Evercore Dae Gon - SVB Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Yasmeen Rahimi - Roth Capital Paul Choi - Goldman Sachs Chris Shibutani - Cowen Mayank Mamtani - B. Riley Akash Tewari - Wolfe Research Madhu Kumar … cardiovascular events. And second, underlying this first need is core patient adherence to LDL-C lowering therapy. Based on the exceptional data presented so far, we believe inclisiran is well positioned to address the significant …

Insmed Announces Closing of Public Offering of Common Stock | PR Newswire | 6/27/2019

… the acquisition or in‑license of additional compounds, product candidates, technology or businesses. Morgan Stanley & Co. LLC, SVB Leerink LLC and Goldman Sachs & Co. LLC acted as joint book-running managers for the offering. Credit Suisse … rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer …

Morgan Stanley

Insmed Announces Closing of Public Offering of Common Stock | PR Newswire | 6/27/2019

… for other general corporate purposes, which may include the acquisition or in‑license of additional compounds, product candidates, technology or businesses. Morgan Stanley & Co. LLC, SVB Leerink LLC and Goldman Sachs & Co. LLC acted as joint … rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer …

Insmed Announces Closing of Public Offering of Common Stock | Business & Finance | heraldchronicle.com | PR Newswire | 6/26/2019

… for other general corporate purposes, which may include the acquisition or in‑license of additional compounds, product candidates, technology or businesses. Morgan Stanley & Co. LLC, SVB Leerink LLC and Goldman Sachs & Co. LLC acted as joint … rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer …

Mayo Clinic

Rebuking FDA, NIH experts say ‘no data’ support plasma as a COVID-19 treatment | FiercePharma | 9/2/2020

… Mayo Clinic, not a controlled clinical trial. And in doing so, the agency relied on an analysis comparing outcomes in patients who received plasma with high titers of SARS-CoV-2 antibodies compared with those who received plasma with low titers. Featured Webinar Increasing Patient Adherence for Isolated Populations During the Pandemic Formulation strategies focused on patient centric solutions featuring several panel speakers representing different perspectives including regulatory, excipients quality …

FDA’s emergency nod for convalescent plasma sparks questions of whether it’s bowing to Trump | FiercePharma | 8/24/2020

… study, not a placebo-controlled trial. Even the FDA itself says “well-controlled randomized trials remain necessary.” Featured Webinar Increasing Patient Adherence for Isolated Populations During the Pandemic Formulation strategies focused on patient centric solutions … U.S. government’s BARDA agency funded the early access program, and Mayo Clinic served as the lead healthcare institution. The FDA’s data are from a single-arm study, which means the plasma treatment wasn’t pitted against …

Harvard Medical School

FDA’s emergency nod for convalescent plasma sparks questions of whether it’s bowing to Trump | FiercePharma | 8/24/2020

… study, not a placebo-controlled trial. Even the FDA itself says “well-controlled randomized trials remain necessary.” Featured Webinar Increasing Patient Adherence for Isolated Populations During the Pandemic Formulation strategies focused on patient centric solutions … placebo—“which hence tells us little,” Adam Gaffney, physician and Harvard Medical School instructor, said on Twitter. The survival improvement number Hahn Quote: d reflects the difference between patients who received plasma with a low …

Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon® Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer | BioSpace | 12/2/2019

… and mortality of CRC comparable to those of USPSTF currently recommended methods. The micro-simulation model, developed and validated at Harvard Medical School, evaluated the impact of adherence rates, testing intervals and clinical performance of … strategies, the results of this micro-simulation model demonstrate that patient adherence and prescribed screening intervals heavily influence the long-term clinical effectiveness for all CRC screening strategies,” said Daniel Sussman, MD, University of Miami …

Banner Health

Current Health Names Former Skyscanner Executive Richard Lennox as Chief Operating Officer | Business Wire | 7/16/2019

… thriving tech sector.” Current Health is partnering with six of the U.S.’s largest health systems, including Mount Sinai and Banner Health, and several NHS Trusts in the U.K. to help reduce hospital readmissions and … with the patient in mind. It has over a 90% patient adherence rate, and they report feeling safer and more secure wearing it. CE-marked in the U.K. and FDA-cleared for both in-hospital …

Current Health Receives FDA Clearance for its Remote Patient Monitoring Solution for In-Home Care, Demonstrates Reduced Hospital Readmissions | Business & Finance | manchestertimes.com | Business Wire | 4/24/2019

… patient adherence. “Real-time, at-home monitoring of vitals allows our team to proactively act on early signs of health decline, preventing avoidable hospitalizations,” said Dr. Neta Faynboym MD, CPE Executive Director, Innovation: Medicare Advantage/Affordability, at Banner Health. Designed specifically with the patient in mind, Current passively measures a patient’s vital signs in real time with its upper-arm wearable. Developed using one of the world’s largest physiological data …

Health Net

Edited Transcript of HSM.TO earnings conference call or presentation 12-Mar-20 9:00pm GMT | Yahoo News | 3/29/2020

… Institute at the KITE Research Institute, the research arm of the Toronto Rehabilitation Institute and a member of the University Health Network or UHN. Let me provide you with a quick agenda for today’s call … conferences and events. We are continuing to gather data on patient adherence and treatment outcomes as part of our strategy to generate the requisite support, demonstrating the quality of life and health economic benefits of …

Highmark Health’s VITAL Innovation Program Validates Effective Drug-Free Treatment for Panic Attacks | PR Newswire | 11/28/2017

… reduced by 50%, ER costs by 64%, and medication costs by 53%(1) PITTSBURGH and DANVILLE, Calif. Highmark Health, Allegheny Health Network and Palo Alto Health Sciences, manufacturer of Freespira, today announced the results of … promising to see high therapist and patient satisfaction and 85% patient adherence 1 , confirming that using Freespira as a first line treatment for panic disorder and panic attacks makes good sense clinically and financially.” About …

Will Lewis

Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options | PR Newswire | 7/24/2020

… the first therapy in both the European Union and the United States for patients with this chronic, debilitating condition,” said Will Lewis , Chairman and Chief Executive Officer of Insmed. “We look forward to potentially bringing … rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer …

Insmed Appoints Carol A. Schafer to its Board of Directors | PR Newswire | 4/2/2020

… as a Managing Partner at Hyphen Advisors, LLC. “We are thrilled to welcome Carol to our Board of Directors,” said Will Lewis , Chairman and CEO of Insmed. “In addition to her strong financial acumen, Carol … rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer …

Kevin Conroy

Exact Sciences Highlights The Opportunity To Seek Screening With Cologuard® Through Telehealth | PR Newswire | 4/2/2020

… we are letting people know they can request Cologuard online from a health care provider, without an office visit,” said Kevin Conroy , Exact Sciences chairman and CEO. “While Americans are at home trying to prevent … future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement and regulatory matters, the anticipated results of our product development efforts and the anticipated benefits of our combination …

Exact Sciences Highlights The Opportunity To Seek Screening With Cologuard® Through Telehealth | Markets Insider | Business Insider | 4/2/2020

… we are letting people know they can request Cologuard online from a health care provider, without an office visit,” said Kevin Conroy , Exact Sciences chairman and CEO. “While Americans are at home trying to prevent … future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement and regulatory matters, the anticipated results of our product development efforts and the anticipated benefits of our combination …

Vas Narasimhan

Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death | Globe Newswire | 11/24/2019

… thirties in the near term and mid-to-high thirties in the medium term Basel, November 24, 2019 — Novartis CEO Vas Narasimhan said: “ We are excited about entering into an agreement to acquire The Medicines … to their healthcare professionals and will likely contribute to improved patient adherence and sustained, lower LDL-C levels 2,3,4 . The Medicines Company expects to file regulatory submissions in the U.S. in the fourth quarter of …

Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death – Company Announcement - FT.com | Financial Times | 11/24/2019

… thirties in the near term and mid-to-high thirties in the medium term Basel, November 24, 2019 — Novartis CEO Vas Narasimhan said: “ We are excited about entering into an agreement to acquire The Medicines … to their healthcare professionals and will likely contribute to improved patient adherence and sustained, lower LDL-C levels 2,3,4 . The Medicines Company expects to file regulatory submissions in the U.S. in the fourth quarter of …

Mark Timney

The Medicines Company (MDCO) CEO Mark Timney on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 10/30/2019

… Q3 2019 Earnings Conference Call October 30, 2019 8:30 AM ET Company Participants Krishna Gorti - Vice President of Investor Relations Mark Timney - Chief Executive Officer Christopher Visioli - Chief Financial Officer Peter Wijngaard - Chief Development Officer … cardiovascular events. And second, underlying this first need is core patient adherence to LDL-C lowering therapy. Based on the exceptional data presented so far, we believe inclisiran is well positioned to address the significant …

Medicines Co (MDCO) Q3 2019 Earnings Call Transcript | The Motley Fool | 10/30/2019

… and welcome to The Medicines Company’s Third Quarter 2019 Earnings Conference Call. I’m joined today by our Chief Executive Officer, Mark Timney; our Chief Financial Officer, Christopher Visioli; our Chief Development Officer, Peter Wijngaard. Earlier … cardiovascular events. And second underlying this first need is poor patient adherence to LDL-C lowering therapy. Based on the exceptional data presented so far, we believe inclisiran is well positioned to address the significant …

Kamal Anand

Fixing Patient Access: Asparia Announces First Chatbot Embedded in Electronic Health Records | Business Wire | 10/8/2019

… Kamal Anand, CEO & Co-Founder, Asparia. “We give a voice to those care needs, whether it’s keeping appointments or getting preventive check-ups. As a result, health systems can manage patient adherence with automated technology.” Today, staff time is wasted on repetitive and ineffective administrative tasks trying to get patients to keep appointments and re-checks. Asparia automates these tasks to improve consistency, adherence and reduces the staff’s administrative burden …

Fixing Patient Access: Asparia Announces First Chatbot Embedded in Electronic Health Records | BioSpace | 10/8/2019

… Kamal Anand, CEO & Co-Founder, Asparia. “We give a voice to those care needs, whether it’s keeping appointments or getting preventive check-ups. As a result, health systems can manage patient adherence with automated technology.” Today, staff time is wasted on repetitive and ineffective administrative tasks trying to get patients to keep appointments and re-checks. Asparia automates these tasks to improve consistency, adherence and reduces the staff’s administrative burden …

Kal Patel

BrightInsight Raises $25 Million to Enhance its Regulated Digital Health Platform and Accelerate Global Commercialization | PR Newswire | 9/5/2019

… BrightInsight Platform has become the leading global regulated digital health platform for the world’s top biopharma and medtech companies,” said Kal Patel , MD, CEO and Co-Founder, BrightInsight. “Our investors have strong pedigrees in healthcare … and actionable insights. It also enables our customers to increase patient adherence and engagement. Having achieved the upmost privacy, security, regulatory and quality certifications, BrightInsight was selected as Novo Nordisk’s global digital health partner to …

BrightInsight, a Flex Company, Receives 2018 Google Cloud Partner of the Year Award for Healthcare and Life Sciences | Business Wire | 4/10/2019

… are honored to be recognized by Google Cloud for the transformative work we are doing with the BrightInsight Platform,” said Kal Patel, MD, President, BrightInsight. “Our platform is built under a Quality Management System to … data and actionable insights to enable customers to drive increased patient adherence and engagement. The BrightInsight™ Platform uses software and services to capture, transmit and analyze data from CE-marked and FDA-regulated medical devices …

William H. Lewis

Insmed Announces Closing of Public Offering of Common Stock | PR Newswire | 6/27/2019

… up to an additional 1,042,307 shares of common stock from Insmed and up to 400,000 shares of common stock from William H. Lewis , the Company’s Chairman and Chief Executive Officer at a public offering price … rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer …

Insmed Announces Closing of Public Offering of Common Stock | Business & Finance | heraldchronicle.com | PR Newswire | 6/26/2019

… up to an additional 1,042,307 shares of common stock from Insmed and up to 400,000 shares of common stock from William H. Lewis, the Company’s Chairman and Chief Executive Officer at a public offering price … rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer …

Omri Shor

AmerisourceBergen’s Lash Group teams up with Medisafe to address patient adherence | MedCity News | 4/29/2019

Health IT , Pharma AmerisourceBergen’s Lash Group teams up with Medisafe to address patient adherence Through their alliance, Medisafe will deliver real-time interventions to help patients stay adherent and will alert Lash Group’s clinicians when … to better engage with patients. In a statement, Medisafe CEO Omri Shor commented: We are excited to move upstream in the patient journey making it easier for new patients to get started on therapy. And …

Lash Group and Medisafe Form Strategic Collaboration to Advance Patient Adherence by Deploying Mobile Engagement Before the First Fill | Malvern Daily Record | 4/29/2019

… of AmerisourceBergen, and Medisafe, a leading medication management platform, today announced that, together, they will provide an end-to-end patient adherence solution that combines a top-rated mobile platform within Lash Group’s current hub … trained clinician is never more than a tap away,” said Omri Shor, CEO of Medisafe. “Our strategic collaboration will improve the well-being of patients with severe illness and complex medication regimens at scale by …